Cohance lifesciences Limited has announced its quarterly earnings conference call to discuss Q3 & 9MFY26 financial results. The pharmaceutical company informed stock exchanges BSE and NSE about the scheduled investor interaction through a regulatory filing dated January 22, 2026.

Conference Call Schedule

The earnings call is scheduled for Thursday, February 12, 2026 at 6:15 PM IST. The session will commence with a brief management discussion on the Q3 & 9MFY26 results, which will be declared earlier on the same day, followed by an interactive Question & Answer session with investors and analysts.

Participation Details

The company has provided comprehensive dial-in information to facilitate participation from domestic and international investors:

Pre-Registration Process

To streamline the connection process, Cohance Lifesciences has enabled pre-registration for participants. Investors can register through the provided link to receive dial-in numbers, passcode, and PIN directly on their registered email addresses. This facility eliminates waiting time for operator assistance during the actual call.

Participants are advised to dial into the conference call 5-10 minutes prior to the scheduled start time to ensure timely connection.

Contact Information

For additional information regarding the conference call, investors can reach out to:

• Cyndrella Carvalho, Head - Investor Relations at Tel: 040 2354 3311, Email: cyndrella.carvalho@cohance.com
• CDR India representatives: Gavin Desa (+91 98206 37649) and Rishab Barar (+91 77770 35061)

The company operates under CIN: L24299MH2018PLC422236 and trades on BSE with scrip code 543064 and NSE with symbol COHANCE. Cohance Lifesciences was formerly known as Suven Pharmaceuticals Limited.

Cohance Lifesciences has reported significant growth in its export operations, demonstrating strong performance in international markets. The pharmaceutical company has shown substantial expansion across both short-term and long-term timeframes.

Export Performance Highlights

Cohance Lifesciences' export division has delivered exceptional results with substantial growth metrics across different measurement periods.

Market Expansion

The 124.00% monthly growth figure represents a significant increase in the company's export business. This substantial short-term growth may indicate strong demand for the company's pharmaceutical products in overseas markets.

The 43.00% yearly growth demonstrates expansion over a longer timeframe, potentially reflecting the company's ability to maintain growth momentum in its export operations. This annual performance might suggest successful market penetration in international territories.

Business Implications

These growth figures highlight Cohance Lifesciences' expansion into international markets and its positioning in the global pharmaceutical sector. The dual growth metrics across different timeframes could indicate both immediate market success and sustained business development capabilities.

The strong export performance may contribute to the company's revenue diversification and potentially reduce dependence on domestic markets, possibly enhancing overall business resilience and growth prospects.

Cohance Lifesciences' reported 124.00% monthly growth and 43.00% yearly growth in exports demonstrates its performance in international markets, potentially solidifying its position in the global pharmaceutical industry.